Glenmark Begins Phase 3 Trial for Ovarian Cancer Drug in India

🧬

has initiated a Phase 3 clinical trial in India for Trastuzumab rezetecan, targeting platinum-resistant ovarian cancer. The study is also planned to expand into Australia and South Korea, subject to the necessary regulatory approvals, marking a significant step in the drug's global development.